azelaprag tirzepatide BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics BioAge rings the changes after

Semaglutide for managing overweight and obesity (TA875) Resource impact report

Durability of histological response and rebound effects A critical unresolved question concerns the durability of histological improvement following treatment interruption or dose reduction

doi: 10.1158/2159-8290.CD-21-0407

A realistic way to think about GLP-1 medications: They improve the environment around lipedema (not the diseased tissue itself) GLP-1 belongs in the category of supportive tools similar to anti-inflammatory diet, metabolic care, and mobility support

Given our current understanding that DHEAS acts as a GABA A receptor antagonist, it is unclear how blocking the GABA A receptor channel blocked the neuroprotective effect of DHEAS